Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140340 | 1.00 | FFAR2 (0.34) | FFAR2NR1H2KDM4EUSP2ALDH1A1 | |
| SCHEMBL710775 | 0.89 | BRD4 (0.33) | FFAR2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL5315549 | 0.89 | BRD4 (0.33) | FFAR2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL15299228 | 0.89 | BRD4 (0.33) | FFAR2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL6627527 | 0.86 | SCN9A (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2198163 | 0.83 | KDM4E (0.36) | NR1H2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14800271 | 0.81 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2199583 | 0.80 | KDM4E (0.42) | NR1H2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL2197047 | 0.79 | KDM4E (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1710717 | 0.78 | LMNA (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-06-26 | — | — | US | disclosed |
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-3204387-B1 | TRIAZOLOPYRAZINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2019-06-12 | — | — | EP | disclosed |
| US-10150771-B2 | Triazolopyrazinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2018-12-11 | — | — | US | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20170298072-A1 | Triazolopyrazinones as PDE1 Inhibitors | H. LUNDBECK A/S (DK) | 2017-10-19 | — | — | US | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2125792-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007143847-A1 | SPIROTROPANE COMPOUNDS | VIROCHEM PHARMA INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-5525619-A | INHIBITORS OF MONOAMINE OXIDASE B | SYNTHELABO (FR) | 1996-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | FFAR2 522/4885NR1H2 1377/4885KDM4E 3896/4885 |
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | FFAR2 898/4885NR1H2 182/4885KDM4E 3304/4885 |
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | FFAR2 638/4885NR1H2 1438/4885KDM4E 2803/4885 |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | LTC4S, STING1, LTB4R2 | FFAR2 1762/4885NR1H2 820/4885KDM4E 4586/4885 |
| US-10150771-B2 | Triazolopyrazinones as PDE1 inhibitors | PDE5A, PDE4A, PDE12 | FFAR2 4164/4885NR1H2 3813/4885KDM4E 1523/4885 |
| US-20170298072-A1 | Triazolopyrazinones as PDE1 Inhibitors | PDE5A, PDE4A, PDE12 | FFAR2 4164/4885NR1H2 3813/4885KDM4E 1523/4885 |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NLRP1 | FFAR2 3223/4885NR1H2 3428/4885KDM4E 3847/4885 |
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | FFAR2 638/4885NR1H2 1438/4885KDM4E 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.